• FAQ
  • Investors
JanOne
  • Why We Exist
  • Pipeline
  • The Pain Truth
  • About PAD
  • Our Company
  • News
  • FAQ
  • Investors
  • FOLLOW THE PROGRESS

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Shareholder Letter
    • FAQ
  • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 24, 2023 11:02am EDT

JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market

Mar 23, 2023 8:30am EDT

JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

Mar 23, 2023 8:00am EDT

JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market

Mar 22, 2023 8:30am EDT

JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

Feb 22, 2023 8:30am EST

JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians

Jan 26, 2023 8:30am EST

JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management

Jan 10, 2023 8:30am EST

JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

Sep 16, 2022 9:30am EDT

JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC

Jun 28, 2022 9:00am EDT

JanOne Inc. Announces an Improved Formulation of JAN101

Jun 07, 2022 8:30am EDT

JanOne Inc. Announces the Issuance of U.S. Patent Covering a Method of Improving Nerve Function Using JAN101

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
JanOne

JanOne is a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. As a result, we hope to reduce the need for prescribing dangerous opioid drugs. Our first drug candidate is a treatment for Peripheral Arterial Disease (PAD), a condition that can cause severe pain and affects over 8.5 million people in the US alone.

The company trades under the symbol JAN on the NASDAQ and continues to independently operate its subsidiary business – Appliance Recycling Centers of America, Inc (ARCA).

Latest News

JanOne on Twitter

  • Why We Exist
  • Pipeline
  • The Pain Truth
  • About PAD
  • Our Company
  • News
  • FAQs
  • Investors
  • Contact